Validity and Reliability of the Thai Version of the 19-Item Compliance-Questionnaire-Rheumatology

Figures & data

Table 1 Baseline Characteristics and Prescribed Medications of 156 Patients with RA

Demographic Characteristics	N = 156
Age (years), mean ± SD	55.9 ± 11.7
Women, N (%)	140 (89.7)
Education (years), median (IQR)	12 (6–16)
Alcohol drinking, N (%)	1 (0.6)
Smoking, N (%)	1 (0.6)
Comorbidities
Diabetes mellitus, N (%)	10 (6.4)
Hypertension, N (%)	48 (30.8)
Dyslipidemia, N (%)	56 (35.9)
Cerebrovascular disease, N (%)	1 (0.6)
Coronary artery disease, N (%)	2 (1.3)
Vitamin D insufficiency/deficiency, N (%)	14 (9.0)
Osteoporosis, N (%)	6 (3.8)
Disease status
Rheumatoid factor, N (%)	111/151 (73.5)
Anti-CCP, N (%)	90/131 (68.7)
Disease duration (years), median (IQR)	9.92 (3.9–15.6)
PGA (0–10), median (IQR)	1 (0.0–3.0)
PhGA (0–10), median (IQR)	0 (0.0–1.0)
ESR, median (IQR)	27 (15.0–48.0)
DAS28 (0–9), median (IQR)	2.67 (2.16–3.40)
HAQ (0–3), median (IQR)	0.13 (0.00–0.63)
Medication
Number of types of DMARDs, N (%)
1	36 (23.1)
2	81 (51.9)
3	37 (23.7)
4	2 (1.3)
Conventional synthetic DMARDs, N (%)	156 (100.0)
Methotrexate, N (%)	134 (85.9)
Sulfasalazine, N (%)	47 (30.1)
Chloroquine, N (%)	60 (38.5)
Hydroxychloroquine, N (%)	14 (9.0)
Leflunomide, N (%)	43 (27.6)
Azathioprine, N (%)	1 (0.6)
Cyclosporin A, N (%)	4 (2.6)
Target synthetic DMARDs, N (%)	5 (3.2)
Tofacitinib, N (%)	3 (1.9)
Baricitinib, N (%)	2 (1.3)
Biologic DMARDs, N (%)	9 (5.8)
Rituximab, N (%)	6 (3.8)
Etanercept, N (%)	3 (1.9)
Prednisolone, N (%)	24 (15.4)

Abbreviations: anti-CCP, anti-cyclic citrullinated peptide; DAS28, disease activity score 28; DMARDs, disease-modifying antirheumatic drugs; ESR, erythrocyte sedimentation rate; HAQ, health assessment questionnaire; IQR, interquartile range; PGA, patient global assessment; PhGA, physician global assessment; SD, standard deviation.

Table 2 Unanswered Question of Thai CQR-19 Questionnaire

Question	N (%)
1	1 (0.6%)
2	4 (2.6%)
3	3 (1.9%)
4	8 (5.1%)
5	3 (1.9%)
6	2 (1.3%)
7	7 (4.5%)
8	11 (7.1%)
9	12 (7.7%)
10	8 (5.1%)
11	16 (10.3%)
12	10 (6.4%)
13	3 (1.9%)
14	8 (5.1%)
15	3 (1.9%)
16	6 (3.8%)
17	2 (1.3%)
18	4 (2.6%)
19	9 (5.8%)

Table 3 Comparison of Medication Compliance Based on the Thai CQR-19 and Pill Count

Thai CQR-19 Results	Medication Compliance^a		Sum
	Poor (N)	Good (N)
Poor (≤ 80%)	5	29	34
Good (> 80%)	13	104	117
Sum	18	133	151

Notes: ^aPill count, poor; taking prescribed drug 80% or less, good; taking prescribed drug more than 80%.

Figure 1 Scatter plot showing the correlation of total Thai CQR-19 and DAS28 scores (A) and HAQ scores (B).